Dossier assessment

Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A18-66
Last updated

Report documents

  1. Extract of dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 120 kB, EN, not accessible
  2. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Dossier assessment

Indication:

Adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant

Result of dossier assessment:

Advantage in overall survival, but also disadvantages in side effects; hint of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A18-66
Commission
Commission awarded on 01.10.2018 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-15
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-14
    Last updated

    Status: Commission completed

  3. Addendum

    Daratumumab (multiple myeloma) - Addendum to Commission A18-66

    Project no.
    A19-16
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-40
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V

    Project no.
    G16-02
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-109
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-127
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-40
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A22-40
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-101
    Last updated

    Status: Commission completed

  11. Dossier assessment

    Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-100
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form